Positions 126–130 of 130.
Right, the Mounjaro question again, but with numbers this time. I have 12 data points over 26 weeks. The pattern is consistent enough that I do not think it is chance,…
Right, the Mounjaro question again, but with numbers this time. I have 2 data points over 40 weeks. The pattern is consistent enough that I do not think it is chance,…
Week 35 update. 16kg down from the start, reflux basically gone since about week 75. Things that worked: consistency, protein at breakfast, walking more than I want to.…
I have had 9 orders now and I keep a table, so here is the honest summary rather than a vibe. Material has been consistent. Communication has not. Shipping has varied…
Send the vial, get the number. Third-party purity and identity testing, results published to you regardless of what they say.
Test a vialSponsoredEst. 1998. ISO 9001 and cGMP, 1,500+ staff, 200+ patents. There is a fair chance the vial you are about to send for testing started here. Batch-specific COA as standard.
glbiochem.netTrying to settle this properly because the thread from last year went in circles. The claim: SURMOUNT matters. The counter-claim: it is measurement error. Both sides…
Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference